Takeda Pharmaceutical (TAK) Short term Debt: 2018-2025

  • Takeda Pharmaceutical's Short term Debt rose 45.19% to $3.6 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $3.6 billion, marking a year-over-year increase of 45.19%. This contributed to the annual value of $3.6 billion for FY2025, which is 41.51% up from last year.
  • Takeda Pharmaceutical's Short term Debt amounted to $3.6 billion in Q1 2025, which was up 45.19% from $2.5 billion recorded in Q1 2024.
  • In the past 5 years, Takeda Pharmaceutical's Short term Debt registered a high of $3.6 billion during Q1 2025, and its lowest value of $1.8 billion during Q1 2022.
  • Its 3-year average for Short term Debt is $2.9 billion, with a median of $2.6 billion in 2023.
  • Per our database at Business Quant, Takeda Pharmaceutical's Short term Debt tumbled by 56.52% in 2021 and then soared by 46.26% in 2023.
  • Over the past 5 years, Takeda Pharmaceutical's Short term Debt (Quarterly) stood at $2.3 billion in 2021, then decreased by 25.10% to $1.8 billion in 2022, then spiked by 46.26% to $2.6 billion in 2023, then decreased by 3.48% to $2.5 billion in 2024, then surged by 45.19% to $3.6 billion in 2025.
  • Its Short term Debt was $3.6 billion in Q1 2025, compared to $2.5 billion in Q1 2024 and $2.6 billion in Q1 2023.